Form 4: Disc Medicine CFO Sells Shares Under 10b5-1 Plan

Disc Medicine's Chief Financial Officer, Jean M. Franchi, sold 353 shares of common stock for a weighted average price of $69.0569 per share.

Summary

• Jean M. Franchi, Chief Financial Officer of Disc Medicine, Inc. (IRON), reported the sale of 353 shares of common stock.
• The transaction occurred on February 25, 2026, at a weighted average price of $69.0569 per share.
• The shares were sold in multiple transactions within a price range of $69.00 to $69.36.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2025.
• Following this transaction, Jean M. Franchi beneficially owns 70,990 shares of Disc Medicine common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a pre-planned transaction under a 10b5-1 plan, which is a routine occurrence for executive liquidity and diversification, rather than a discretionary sale based on new information.

Positives

• The transaction was executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale for diversification or liquidity rather than a discretionary sale based on new negative information.

Negatives

• An insider sale, even if pre-planned, reduces the officer's direct equity stake in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider sales, especially when conducted under a pre-arranged Rule 10b5-1 plan, are common for executive compensation management and personal financial diversification. Such transactions typically do not signal a change in the company's fundamental prospects or a negative outlook, as they are scheduled in advance to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders: Minimal direct impact, as this is a routine, pre-planned insider sale for personal financial management.

Key Dates

Recommendation

The sale by the Chief Financial Officer was executed under a pre-arranged 10b5-1 trading plan, which typically indicates a planned liquidity event rather than a change in sentiment about the company's prospects. Therefore, it does not provide a strong signal for a change in investment recommendation.

Keywords

Disc Medicine, IRON, Insider Trading, Form 4, Stock Sale, CFO, Jean M. Franchi, 10b5-1 Plan